PrabotulinumtoxinA-Xvfs FDA approval date

The FDA approved PrabotulinumtoxinA-Xvfs (Jeuveau) on 1 Feb 2019.

FDA approval date
1 Feb 2019

Drug identity checked against registry records

Also recorded as Jeuveau

Included trials

TrialSponsorPhaseStatusPrimary completion
Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar LinesNCT05320393EOLSPhase 2Completed2023-05-22Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2019-02-01DayPrabotulinumtoxinA-XvfsEvolus, Inc. · EOLSFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA761085", "applicant_as_listed_by_fda": "EVOLUS INC", "brand_names": ["JEUVEAU"], "active_ingredients": ["PRABOTULINUMTOXINA-XVFS"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20190201", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026